Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of benzenesulfonamides, characterized by containing sulfonamide groups. It has a molecular formula of C14H15N3O5S2 and an average molecular weight of approximately 369.42 g/mol. The drug is experimental and not approved for clinical use in any country. It has no known patents or indicated conditions, and no clinical trials beyond phase 0 have been reported. Mechanistically, it acts as an inhibitor of carbonic anhydrase 2 (CA II), with a reported binding affinity (Ki) around 12 nM, indicating potent inhibition activity against this enzyme. Carbonic anhydrase inhibitors are typically used to modulate pH balance and fluid secretion in various tissues but specific therapeutic indications for this compound are not established. No developer or manufacturer information is available publicly, reflecting its experimental status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide.